Abstract
Background Cirrhosis is the main risk factor for the development of Hepatocellular carcinoma (HCC). Six-monthly screening with ultrasound is advocated for the surveillance of cirrhotic patients. We recently showed that a glycomics-based test (GlycoCirrhoTest [GCT]) can provide additional information regarding the risk of HCC development in cirrhotic patients.
Aims Independent clinical validation of the GCT for the assessment of the risk of HCC development in cirrhosis and exploration of additional clinical parameters to assess HCC risk.
Methods Validation study on serum samples of patients with established compensated cirrhosis (CHILD Pugh A & B) in a tertiary liver centre. Serum N-glycan profiling was performed and GCT was calculated at baseline. During the follow up period, patients were screened for the presence of HCC every 6 months with ultrasound.
Results A total of 198 cirrhotic patients were followed in clinical routine for the development of HCC. 29 patients developed HCC and one died during follow up. At baseline, the mean GCT value was significantly higher in patients who developed HCC within 3 years compared to patients who did not develop HCC (Welch’s t-test, p-value 3 years: 0.034). A high GCT at baseline was associated with increased HCC incidence with a HR of 5.8 (95% CI: 0.7 – 48), 4.8 (95% CI: 1.4 – 16) and 3.6 (95% CI: 1.2 – 11) at 3, 5 and 7 years post sampling respectively. Results from this study are in agreement with previous results1, as shown in a meta-analysis. Moreover, we also identified albumin as an independent predictor for developing HCC in a multivariate analysis revealing that low albumin blood levels (< 4g/dL) are also associated with increased HCC incidence with a HR at 7 years of 2.3 (95% CI: 1.1 - 4.9). For subjects with both high GCT and low albumin we found a HR of 9.8 (95% CI: 3.5 to 27) at 7 years.
Conclusions GCT is a glycomics-based test that provides additional information for risk assessment of HCC development in cirrhosis. This information could be used to develop personalised HCC screening programs in cirrhotic patients according to the value of GCT. Serum albumin levels could provide additional and GCT-independent information which may add to the utility of the test.
Competing Interest Statement
Nico Callewaert is inventor on a patent family for the use of GlycoCirrhoTest in the diagnosis of compensated liver cirrhosis.
Funding Statement
This study has received funding from the Grand Challenges Program of VIB. This VIB Program received support from the Flemish Government under the Management Agreement 2017-2021 (VR 2016 2312 Doc.1521/4). XV received a translational and clinical mandate from Stichting tegen Kanker Belgium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of UZ Ghent (Ghent University Hospital) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses, Leander Meuris: Leander.Meuris{at}UGent.vib.be, Roos Colman: Roos.Colman{at}UGent.be, Anja Geerts: anja.geerts{at}UGent.be, Annelies Van Hecke: Annelies.Vanhecke{at}UGent.vib.be, Hans Van Vlierberghe: Hans.VanVlierberghe{at}UZGent.be, Nico Callewaert: Nico.Callewaert{at}UGent.vib.be
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
